Rein Therapeutics (RNTX) Free Cash Flow (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Free Cash Flow of -$3.4 million for Q1 2026, up 44.55% year-over-year from -$2.4 million in Q1 2025, and down 6.34% quarter-over-quarter from -$3.2 million in Q4 2025.
Rein Therapeutics (RNTX) Free Cash Flow (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Free Cash Flow for 11 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 44.55% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$16.6 million (up 28.39% YoY), while the FY2025 annual figure was -$19.4 million, up 13.14% from the prior year.
- Free Cash Flow slipped to -$3.4 million in Q1 2026 per RNTX's latest filing, from -$3.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.6 million in Q3 2023 and bottomed at -$10.4 million in Q4 2023.
- Historically, Free Cash Flow has averaged -$5.3 million across 5 years, with a median of -$4.8 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow surged 76.47% — and 2024, when it sank 169.22%.
- Rein Therapeutics' Free Cash Flow stood at -$4.4 million in 2022, then slumped by 135.68% to -$10.4 million in 2023, then soared by 53.69% to -$4.8 million in 2024, then soared by 33.08% to -$3.2 million in 2025, then slipped by 6.34% to -$3.4 million in 2026.
- Business Quant data shows RNTX's Free Cash Flow at -$3.4 million in Q1 2026, -$3.2 million in Q4 2025, and -$3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.64 Mn |
| Jun 30, 2026 | -8.64 Mn |
| Mar 31, 2026 | -3.42 Mn |
| Mar 31, 2026 | -3.42 Mn |
| Dec 31, 2025 | -3.22 Mn |
| Dec 31, 2025 | -3.22 Mn |
| Sep 30, 2025 | -3.55 Mn |
| Sep 30, 2025 | -3.55 Mn |
| Jun 30, 2025 | -6.42 Mn |
| Jun 30, 2025 | -6.42 Mn |
| Mar 31, 2025 | -6.18 Mn |
| Mar 31, 2025 | -6.18 Mn |
| Dec 31, 2024 | -4.81 Mn |
| Dec 31, 2024 | -4.81 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Jun 30, 2024 | -8.39 Mn |
| Jun 30, 2024 | -8.39 Mn |
| Mar 31, 2024 | -5.27 Mn |
| Mar 31, 2024 | -5.27 Mn |